Compare GPOR & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPOR | BLLN |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.2B |
| IPO Year | 1998 | N/A |
| Metric | GPOR | BLLN |
|---|---|---|
| Price | $200.13 | $71.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $228.13 | $129.57 |
| AVG Volume (30 Days) | ★ 367.8K | 326.1K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 245.92 | N/A |
| EPS | ★ 21.48 | N/A |
| Revenue | ★ $1,422,583,000.00 | N/A |
| Revenue This Year | $17.88 | $35.42 |
| Revenue Next Year | $6.71 | $32.30 |
| P/E Ratio | $9.15 | ★ N/A |
| Revenue Growth | ★ 48.47 | N/A |
| 52 Week Low | $153.41 | $61.96 |
| 52 Week High | $225.78 | $138.70 |
| Indicator | GPOR | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 42.04 |
| Support Level | $199.96 | $66.00 |
| Resistance Level | $215.65 | $100.28 |
| Average True Range (ATR) | 7.98 | 6.53 |
| MACD | -1.10 | -0.49 |
| Stochastic Oscillator | 37.07 | 34.84 |
Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets predominantly located in the Appalachia and Anadarko basins in the United States. Its principal properties are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.